Article year (reference) | No. of subjects | Duration of follow-up (months) | Baseline assessment modality | Outcome parameter assessed | Results |
---|---|---|---|---|---|
2008127 | 102 | 12 | Ultrasound SH, PD synovitis | CR progression (Genant score) | SH: OR 2.31, p 0.032 PD synovitis: OR 12.21, p<0.001 |
MRI synovitis | OR 2.98, p 0.002 | ||||
2011128 | 94 | 12 | Ultrasound SH, PD synovitis, remissions (no SH or PD synovitis) | Relapse rate | % patients having flare: in ultrasound remission: 20.0% With ultrasound PD activity: 47.1%, p 0.009 |
2009129 | 106 | 24 | Ultrasound joint count, PD synovitis | Relapse rate | Unsustained remission vs sustained remission: higher PD: OR 12.8, p<0.05 Higher ultrasound joint count: OR 4.6, p<0.05 |
2005130 | 32 | 12 | Ultrasound RI | Relapse rate | Relapse rate higher with low RI se 0.80, sp 1.0, acc 0.96, p<0.01 |
2007131 | 169 | 24 | Sustained ACR/DAS remission | CR progression (Larsen score) | Increase in Larsen score in (unsustained vs sustained): ACR remission: p 0.017 DAS remission: p<0.001 |
2004132 | 187 | 24 | Sustained ACR/DAS remission | CR progression (SHS) | Increase in SHS score in (unsustained vs sustained): ACR remission: p 0.053 DAS remission: p 0.017 |
2012133 | 535 | 24 | Remission according to DAS, SDAI, CDAI, ACR/EULAR | CR progression (SHS) | % patients with CR progression with baseline remission: DAS: 30% SDAI: 24% CDAI: 19% ACR/EULAR: 20% |
ACR, American College of Rheumatology; CDAI, clinical disease activity index; CR, conventional radiography; DAS, disease activity score; EULAR, European League Against Rheumatism; PD, power Doppler; RI, resistive index; SDAI, simplified disease activity index; SH, synovial hypertrophy; SHS, Sharp/van der Heijde score.